Who Generates Higher Gross Profit? Incyte Corporation or Jazz Pharmaceuticals plc

Incyte vs. Jazz: A Decade of Gross Profit Growth

__timestampIncyte CorporationJazz Pharmaceuticals plc
Wednesday, January 1, 20145084910001055457000
Thursday, January 1, 20157267790001222277000
Friday, January 1, 201610475320001382587000
Sunday, January 1, 201714567370001508505000
Monday, January 1, 201817877600001769378000
Tuesday, January 1, 201920445100002033831000
Wednesday, January 1, 202025353740002214650000
Friday, January 1, 202128352760002653478000
Saturday, January 1, 202231876380003118857000
Sunday, January 1, 202334406490003398627000
Monday, January 1, 20243929149000
Loading chart...

Infusing magic into the data realm

A Decade of Growth: Incyte Corporation vs. Jazz Pharmaceuticals

In the competitive landscape of the pharmaceutical industry, gross profit is a key indicator of a company's financial health and operational efficiency. Over the past decade, Incyte Corporation and Jazz Pharmaceuticals plc have been neck and neck in their quest for higher gross profits. From 2014 to 2023, both companies have shown remarkable growth, with Incyte Corporation's gross profit increasing by approximately 577% and Jazz Pharmaceuticals by about 222%.

In 2014, Jazz Pharmaceuticals led the race with a gross profit of around $1.06 billion, nearly double that of Incyte. However, by 2023, Incyte had closed the gap, generating a gross profit of approximately $3.44 billion, slightly edging out Jazz Pharmaceuticals' $3.40 billion. This shift highlights Incyte's strategic advancements and market adaptability, making it a formidable competitor in the pharmaceutical sector.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025